
According to a piece by Bloomberg, Allergan is looking at options to divest its women’s health unit in a move …

AstraZeneca’s biologic R&D unit MedImmune is set to enter a partnership with Israeli drug firm Compugen to develop bi-specific and …

Celgene has had a rough six months, its share price since the beginning of October has dropped from $146 to …

As we approach the Easter weekend, we at Pharmafocus hope all of our readers have a great long weekend, if …

Biotech companies showing faith in their own prospect drug candidates is not an unusual occurrence, some do it to extremes. …

Teva has been spared a sizeable payout to GlaxoSmithKline after a federal judge overturned a US jury verdict demanding that …

Fujifilm has made no secret of the fact it is looking to switch up part of its core business to …

Takeda is considering making a bold move for Shire, after announcing, as per UK regulations, that it may make an …

Israeli drug firm CureTech is be sold for the third time in four years, this time to InSight Innovations in …

Roche has been rocked by the revelation that there have been five patient deaths linked to the use of its …

Pfizer has submitted proposals to officials in Portage, Michigan, for a major expansion of its manufacturing site in the city. …

After the news broke earlier in the week of a group of nearly 100 MPs calling for a parliamentary commission …

On behalf of the Brexit Health Alliance, Sarah Collen, Senior Policy Manager at NHS Confederation, details the potential negative fallout …

The discovery of an entirely new organ, the 80th to be discovered in the human body, could have serious implications …

Abbvie has been ordered to pay over $3 million in damages to a man who asserts that the uise of …

Biohaven is full of confidence in its lead drug, rimegepant, evidenced only a few weeks ago when it decided to …

GSK has announced that it plans to purchase Novartis’ 36.5% stake in the joint Consumer Healthcare Business for a sum …

As we finally pass into Spring after what still feels like a particularly stubborn Winter, we are pleased to announce …

Seattle Genetics and Astellas have confirmed that the drug candidate they are co-developing, enfortumab, has been given FDA breakthrough therapy …

Ablynx has revealed that its interleukin 6 pathway via its IL-6 receptor (IL-6R) vobarilizumab failed to meet its primary endpoint …